Azithromycin for bronchial asthma in adults: An effectiveness trial

Journal of the American Board of Family Medicine

Volumn 25, Issue 4, 2012, Pages 442-459

  Hahn, David L ^a,b   Grasmick, Mike ^b   Hetzel, Scott ^b   Yale, Steven ^c  

^a Dean East Clinic   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c MARSHFIELD CLINIC   (United States)

Author keywords

Antibiotics; Asthma; Clinical trials, randomized; Infectious diseases; Practice based research networks

Indexed keywords

AZITHROMYCIN; BRONCHODILATING AGENT; CLARITHROMYCIN; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; PREDNISONE; ROXITHROMYCIN;

ADULT; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEARING LOSS; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEVERE PERSISTENT ASTHMA; STOMACH PAIN; SWELLING; SYMPTOMATOLOGY; TREATMENT OUTCOME; VAGINA CANDIDIASIS; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; ASTHMA; AZITHROMYCIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 84863670329     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2012.04.110309     Document Type: Article

References (42)

1. Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005;(3):CD002997.
2. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 2011;81:67-74.
3. Johnston SL, Martin RJ. Chlamydophila pneumoniae and Mycoplasma pneumoniae. A role in asthma pathogenesis? Am J Respir Crit Care Med 2005;172:1078-89. (Pubitemid 43066642)
4. Herland K, Akselsen J-P, Skjønsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med 2005;99:11-9. (Pubitemid 40017378)
5. Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007;62:219-23.
6. Demoly P, Gueron B, Annunziata K, Adamek L, Walters RD. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev 2010;19:150-7.
7. Global Initiative for Asthma (GINA) 2007. Global Strategy for Asthma Management and Prevention. Updated 2007. GINA Executive Committee, 92 pages.
8. American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. Am J Resp Dis 1991;144:1202-18.
9. Dekker FW, Schrier AC, Sterk PJ, Dijkman JH. Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction. Thorax 1992;47:162-6.
10. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999;115:1265-70. (Pubitemid 29230632)
11. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7. (Pubitemid 29519356)
12. Juniper EF, O'Byrne PM, Roberts JN. Measuring asthma control in group studies: do we need airway calibre and rescue beta2-agonist use? Respir Med 2001;95:319-23. (Pubitemid 32624474)
13. Hahn DL. An unanticipated effect of clinical trial registration. BMJ [serial online] Available from: http://www.bmj.com/content/325/7376/1314?tab= responses, 2007. Accessed April 27, 2012.
14. Juniper EF, Guyatt GH, Willan A, Griffeth LE. Determining a minimal important change in a disease-specific quality of life instrument. J Clin Epidemiol 1994;47:81-7. (Pubitemid 24034293)
15. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363:1715-26.
16. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic cost of asthma. Am J Resp Crit Care Med 1997;156:787-93. (Pubitemid 27396416)
17. Shoji T, Yoshida S, Sakamoto H, Hasegawa H, Nakagawa H, Amayasu H. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999;29:950-6. (Pubitemid 29317806)
18. Amayasu H, Yoshida S, Ebana S, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000;84:594-8. (Pubitemid 30418859)
19. Black PN, Blasi F, Jenkins CR, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001;164:536-41. (Pubitemid 32801652)
20. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma. Effect of clarithromycin. Chest 2002;121:1782-8. (Pubitemid 34634396)
21. Kostadima E, Tsiodras S, Alexopoulos EI, et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004;23:714-7. (Pubitemid 38618141)
22. Hahn DL, Plane MB, Mahdi OS, Byrne GI. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials 2006;1:e11.
23. Piacentini GL, Peroni DG, Bodini A, et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc 2007;28:194-8.
24. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148-55.
25. Strunk RC, Bacharier LB, Phillips BR, et al. Azithromycin or montelukast as inhaled corticoste-roid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol 2008;122:1138-44.
26. Sutherland ER, King TS, Icitovic N, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010;126:747-53.
27. von Hertzen L, Vasankari T, Liippo K, Wahlström E, Puolakkainen M. Chlamydia pneumoniae and severity of asthma. Scand J Infect Dis 2002;34:22-7. (Pubitemid 34141500)
28. Hahn DL, Golubjatnikov R. Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb 1992;12:945-7.
29. Pasternak R, Huhtala H, Karjalainen J. Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: a longitudinal analysis. J All Clin Immunol 2005;116:1123-8. (Pubitemid 41571798)
30. Brandén E, Koyi H, Gnarpe H, Tornling G. Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD. Respir Med 2005;99:20-6. (Pubitemid 40017379)
31. Hahn DL. Infectious asthma: a reemerging clinical entity? J Fam Pract 1995;41:153-7.
32. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005;352:1637-45. (Pubitemid 40530230)
33. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithomycin for the secondary prevention of coronary heart disease events: the WIZARD Study: a randomized controlled trial. JAMA 2003;290:1459-66. (Pubitemid 37430400)
34. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
35. Hahn DL. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:2235-7.
36. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991;91:5S-11S.
37. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004;17:59-67.
38. Hahn DL. Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial. J Fam Pract 1995;41:345-51.
39. Aronson N, Lefevre F, Piper M, et al. Management of chronic asthma. Evidence report/technology assessment number 44. AHRQ publication no. 01-E044. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
40. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials. Increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-32. (Pubitemid 37430387)
41. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic - explanatory continuum indicator summary (PREVIS): a tool to help trial designers. J Clin Epidemiol 2009;62:464-75.
42. Rollins DR, Beuther DA, Martin RJ. Update on infection and antibiotics in asthma. Curr Allergy Asthma Rep 2010;10:67-73.